Sagimet Biosciences Inc. Class A (SGMT)

Sagimet Biosciences' stock has been impacted by several events in the past six months. The company reported a GAAP EPS loss of -$0.40 per share in Q3 2025, which caused the stock price to decrease. Positive news catalysts, including positive Phase 3 acne data from its partner in China, FDA Breakthrough Therapy designation for denifanstat in MASH, and positive Phase 2 Fascinate-2 results for MASH, have contributed to stock momentum. The share price increased by 35.74% between January 13, 2025, and January 9, 2026, but also experienced a -35.00% change over the last 6 months as of the current time. Significant open-market selling from key executives has contributed to a negative insider sentiment.

As a clinical-stage biopharmaceutical company, Sagimet Biosciences Inc. primarily focuses on drug discovery and development, with its revenue largely stemming from strategic licensing payments rather than direct product sales. Therefore, traditional demand seasonality is not directly applicable to Sagimet Biosciences' current business model. The company's financial performance is more influenced by clinical trial progress, regulatory milestones, and research and development investments.

Sagimet Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and liver diseases. The company operates within the biotechnology sector and its core business involves the discovery and development of small molecule inhibitors targeting fatty acid synthase (FASN). Its lead product candidate, Denifanstat, is in development for the treatment of MASH and has received Breakthrough Therapy designation from the FDA for non-cirrhotic MASH with moderate to advanced liver fibrosis. It is also being explored for the treatment of moderate to severe acne vulgaris and recurrent glioblastoma multiforme. TVB-3567 is another FASN inhibitor in the pipeline, also being explored for the treatment of acne and select forms of cancer. Sagimet is also developing FASN inhibitors for various solid tumors and glioblastoma.

Sagimet Biosciences Inc. is headquartered in San Mateo, California, and develops therapeutics in the United States. The company also has a license partner, Ascletis BioScience Co. Ltd., which is testing denifanstat in China for moderate to severe acne vulgaris and recurrent glioblastoma multiforme.

Sagimet Biosciences' brand reputation has been positively influenced by a series of favorable developments and announcements in the past year. Positive results from clinical trials, including the successful completion of the Phase 2b FASCINATE-2 trial of denifanstat in MASH and positive Phase 3 acne data from its partner in China, have boosted the company's reputation. The FDA's Breakthrough Therapy designation for denifanstat in MASH significantly bolstered its reputation and market sentiment. Sagimet Biosciences actively participates in industry conferences, presenting posters and announcing positive results, such as at the 10th Annual MASH-TAG 2026 Conference and the announcement of a global license agreement for innovative forms of Resmetirom API.

Sagimet Biosciences Inc. has a mixed ownership structure comprising institutional, retail, and individual investors. Approximately 26.40% to 38.85% of the company's stock is owned by institutional investors, including Woodline Partners LP, Blue Owl Capital Holdings LP, and Vanguard Group Inc. Insiders own between 10.06% and 66.79% of the stock, with Patrick J. Kerins reported as the largest individual shareholder.